Monopar Therapeutics Inc.
MNPR
$113.04
$2.632.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.04% | -21.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.16% | -15.11% | |||
| Operating Income | -27.16% | 15.11% | |||
| Income Before Tax | -36.48% | 25.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.48% | 25.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.48% | 25.14% | |||
| EBIT | -27.16% | 15.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -36.37% | 25.16% | |||
| Normalized Basic EPS | -36.34% | 25.15% | |||
| EPS Diluted | -36.37% | 25.16% | |||
| Normalized Diluted EPS | -36.34% | 25.15% | |||
| Average Basic Shares Outstanding | 0.08% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||